Drug Trial Radar · NCT01261325
Brivaracetam Efficacy and Safety Study in Subjects With Partial Onset Seizures
Last checked: Nov 20, 2026Latest source record: Jul 22, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
768
Actual
Start
Dec 2010
Primary completion
May 2014
Study completion May 2014
Sponsor
- Lead sponsor
- UCB PharmaUCB
- Sponsor type
- Industry
- First posted
- Dec 16, 2010
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 16 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate the efficacy and safety of brivaracetam at doses of 100 and 200mg/day compared to placebo as adjunctive treatment in adult focal epilepsy subjects with partial onset seizures not fully controlled despite current treatment with 1 or 2 concomitant antiepileptic drugs.
Conditions
- Epilepsy
Interventions
PlaceboDrug
Daily oral dose of two equal intakes of placebo in a double-blinded way for the 12-week treatment period
BrivaracetamDrug
Daily oral dose of two equal intakes of Brivaracetam 100 mg/ day in a double-blinded way for the 12-week treatment period
BrivaracetamDrug
Daily oral dose of two equal intakes of Brivaracetam 200 mg/ day in a double-blinded way for the 12-week treatment period.
Antiepileptic drugs with market authorization available per countryDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent Reduction Over Placebo for Partial Onset Seizure (Type I) Frequency Over the Treatment Period Standardized to a 28-day DurationTime frame: 12 week Treatment Period
- 50% Responder Rate for Partial Onset Seizure (Type I) Frequency Over the Treatment Period Standardized to a 28-day DurationTime frame: Baseline to 12 week Treatment Period
Locations
207 sites in 28 countries. Site status is shown where the registry gives one.
001
Phoenix, Arizona
013
Phoenix, Arizona
006
Tucson, Arizona
775
Little Rock, Arkansas
045
Sacramento, California
025
San Francisco, California
060
Aurora, Colorado
085
Colorado Springs, Colorado
071
Miami, Florida
110
Miami, Florida
073
Naples, Florida
090
Ocala, Florida
027
Orlando, Florida
064
Port Charlotte, Florida
044
Sarasota, Florida
023
Atlanta, Georgia
063
Atlanta, Georgia
062
Columbus, Georgia
048
Rome, Georgia
039
Boise, Idaho
005
Peoria, Illinois
017
Winfield, Illinois
020
Ames, Iowa
069
Iowa City, Iowa
780
Lexington, Kentucky
092
Hammond, Louisiana
008
Bethesda, Maryland
068
Waldorf, Maryland
055
East Lansing, Michigan
009
Golden Valley, Minnesota
051
Missoula, Montana
032
Lebanon, New Hampshire
042
Hamilton, New Jersey
058
Voorhees Township, New Jersey
095
Kingston, New York
022
New York, New York
099
New York, New York
098
Poughkeepsie, New York
010
Asheville, North Carolina
003
Durham, North Carolina
Showing 40 of 207 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.